Patents Issued in September 15, 2020
  • Patent number: 10774073
    Abstract: The invention relates to inhibitors of dihydrofolate reductase and pharmaceutical preparations thereof. The invention further relates to methods of treatment of parasitic infections, such as T. gondii, T. cruzi, P. falciparum, T. brucei, or L. major infections, using the novel inhibitors of the invention.
    Type: Grant
    Filed: February 2, 2017
    Date of Patent: September 15, 2020
    Assignee: Vyera Pharmaceuticals, LLC
    Inventors: Stephen B. Thomas, Allen T. Hopper, Matthew Welsch
  • Patent number: 10774074
    Abstract: Compounds of formula I, wherein A is an optionally substituted five-membered unsaturated heterocyclic ring containing 1, 2, or 3 N, O, or S ring heteroatom(s) exhibit alpha2C antagonistic activity and are thus useful for the treatment of diseases or conditions of the peripheric or central nervous system.
    Type: Grant
    Filed: June 3, 2016
    Date of Patent: September 15, 2020
    Assignee: ORION CORPORATION
    Inventors: Shouming Wang, Esa Kumpulainen, Jarmo Pystynen, Antti Pohjakallio, Anssi Haikarainen
  • Patent number: 10774075
    Abstract: This disclosure relates to compositions including certain compounds identified by a quantitative, high throughput assay to be effective in the treatment of a Rac-GTPase mediated disorder (e.g., acute lymphoblastic or chronic myelogenous leukemia), as well as methods for the manufacture of and the use of these compounds for treating a Rac-GTPase mediated disorder.
    Type: Grant
    Filed: April 15, 2016
    Date of Patent: September 15, 2020
    Assignee: Children's Medical Center Corporation
    Inventors: David A Williams, Serena De Vita
  • Patent number: 10774076
    Abstract: Disclosed are novel benzazole compounds and compositions comprising the compounds. The compounds are useful as kinase inhibitors including interleukin receptor associated kinases (IRAK) inhibitors. Also disclosed are methods of making and using the compounds and compositions. The disclosed compounds and/or compositions may be used to treat or prevent an IRAK-associated disease or condition.
    Type: Grant
    Filed: August 7, 2018
    Date of Patent: September 15, 2020
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Rose Yen, Yan Chen, Rajinder Singh, Vanessa Taylor
  • Patent number: 10774077
    Abstract: The invention relates to a compound comprising the following general formula (1): and said compound for use as a medicament, in particular for use in the treatment psychiatric or neurological disorders and inflammation, in particular neuroinflammation: (formula 1) wherein each of R1, R2 and R3 are selected independently from each other from alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, aryl, heterocycle, or heteroaryl.
    Type: Grant
    Filed: August 21, 2019
    Date of Patent: September 15, 2020
    Assignee: UNIVERSITAT BERN
    Inventors: Jean-Louis Reymond, Simon Nicolussi, Jurg Gertsch
  • Patent number: 10774078
    Abstract: The present invention relates to novel compounds and methods for the manufacture of inhibitors of deubiquitylating enzymes (DUBs). In particular, the invention relates to the inhibition of ubiquitin C-terminal hydrolase L1 (UCHL1). The invention further relates to the use of DUB inhibitors in the treatment of cancer and other indications. Compounds of the invention include compounds having the formula (I) or a pharmaceutically acceptable salt thereof, wherein R1 to R8 are as defined herein.
    Type: Grant
    Filed: June 21, 2019
    Date of Patent: September 15, 2020
    Assignee: MISSION THERAPEUTICS LTD
    Inventors: Alison Jones, Mark Ian Kemp, Martin Lee Stockley, Karl Richard Gibson, Gavin Alistair Whitlock, Andrew Madin
  • Patent number: 10774079
    Abstract: Provided are a quinazoline derivative, a pharmaceutical composition containing the same, a method for preparation of said derivative, and an application of same as an anti-cancer drug.
    Type: Grant
    Filed: August 8, 2019
    Date of Patent: September 15, 2020
    Assignee: CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD.
    Inventors: Ying Shi, Qingzhi Gao, Xiaozhuo Chen, Yi Mi, Yaran Zhang, Hanyu Yang, Yujie Chen, Chunlei Liu, Guorui Mi, Yuxiu Ma, Dongmin Shen, Yang Guo, Linjing Fan
  • Patent number: 10774080
    Abstract: The invention provides a compound of formula (I): or a pharmaceutically-acceptable salt thereof, that is an inhibitor of JAK kinases. The invention also provides pharmaceutical compositions comprising such compound, a crystalline form, methods of using such compound to treat inflammatory skin diseases and other diseases, and processes and intermediates useful for preparing such compound.
    Type: Grant
    Filed: January 8, 2020
    Date of Patent: September 15, 2020
    Assignee: Theravance Biopharma R&D IP, LLC
    Inventors: Jennifer Kozak, Ryan Hudson
  • Patent number: 10774081
    Abstract: Disclosed in the present invention is a type of indole substituted piperidine compounds as an estrogen receptor down-regulator. Specifically disclosed are a compound as shown in formula (I), a pharmaceutically acceptable salt, hydrate or prodrug thereof, a preparation method therefor, a pharmaceutical composition thereof, and a use thereof as an estrogen receptor down-regulator in the treatment of estrogen receptor positive breast cancers.
    Type: Grant
    Filed: October 30, 2017
    Date of Patent: September 15, 2020
    Assignees: LUOXIN PHARMACEUTICAL (SHANGHAI) CO., LTD., SHANDONG LUOXIN PHARMACEUTICAL GROUP STOCK CO., LTD.
    Inventors: Jianyu Lu, Charles Z. Ding, Xu Zeng, Huijun He, Shuhui Chen, Lihong Hu, Jiaqiang Dong, Tie-Lin Wang
  • Patent number: 10774082
    Abstract: [Problem] Provided is a compound which is useful as an active ingredient of a pharmaceutical composition for treating lung cancer. [Means for Solution] The present inventors have studied a compound useful as an active ingredient of a pharmaceutical composition for treating lung cancer, and as a result, it was found that a quinazoline compound has an excellent G12C mutation KRAS inhibitory activity, and which can be used as a therapeutic agent for lung cancer, and thereby the present invention has been completed. The quinazoline compound of the present invention and a salt thereof may be used as the therapeutic agent for lung cancer.
    Type: Grant
    Filed: December 12, 2019
    Date of Patent: September 15, 2020
    Assignee: Astellas Pharma Inc.
    Inventors: Kazuyuki Kuramoto, Michinori Akaiwa, Tomoaki Abe, Takanobu Araki, Susumu Yamaki, Shigeki Kunikawa, Tomoyoshi Imaizumi, Takahiro Nigawara, Keisuke Arakawa, Itsuro Shimada, Masashi Shimazaki, Yoshiki Satake, Kazushi Watanabe, Takanori Koike
  • Patent number: 10774083
    Abstract: Provided is a heterocyclic amide compound that may have a PRS inhibitory action and is expected to be useful as a prophylactic or therapeutic agent for PRS associated diseases and the like including cancer. A compound represented by the following formula (I): wherein a group represented by is a group represented by the following formula (II) or the following formula (III): and other symbols are as described in the DESCRIPTION, or a salt thereof.
    Type: Grant
    Filed: September 14, 2017
    Date of Patent: September 15, 2020
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Takaharu Hirayama, Yasuhiro Hirata, Yusuke Tominari, Naoki Iwamura, Yusuke Sasaki, Moriteru Asano, Terufumi Takagi, Masanori Okaniwa, Shinichi Imamura
  • Patent number: 10774084
    Abstract: Adenine derivatives substituted at the C2, N6, and N9 purine positions having antisenescent and combined photoprotective UVA/UVB effects. These substances are particularly suitable as anti-senescent and UV-photoprotective component in cosmetic preparations, plant protection preparations and in preparations for the treatment/application of tissue cultures.
    Type: Grant
    Filed: August 24, 2016
    Date of Patent: September 15, 2020
    Assignee: UNIVERZITA PALACKEHO V OLOMOUCI
    Inventors: Martin Hönig, Lucie Plihalova, Karel Dolezal, Jiri Voller, Miroslav Strnad, Lukas Spichal, Jitka Vostalova, Alena Rajnochova Svobodova, Jitka Ulrichova, Alena Kadlecova, Ondrej Plihal
  • Patent number: 10774085
    Abstract: Compounds useful in the synthesis of compounds for treating pain, cancer, inflammation, neurodegenerative disease or Typanosoma cruzi infection in a mammal.
    Type: Grant
    Filed: July 25, 2018
    Date of Patent: September 15, 2020
    Assignee: ARRAY BIOPHARMA INC.
    Inventors: Julia Haas, Steven W. Andrews, Yutong Jiang, Gan Zhang
  • Patent number: 10774086
    Abstract: The disclosure generally relates to compounds of formula (I), including their salts, as well as compositions and methods of using the compounds to treat disorders associated with GSK-3.
    Type: Grant
    Filed: November 27, 2017
    Date of Patent: September 15, 2020
    Assignee: Bristol-Myers Squibb Company
    Inventors: Richard A. Hartz, Vijay T. Ahuja, Prasanna Sivaprakasam, Gene M. Dubowchik, John E. Macor
  • Patent number: 10774087
    Abstract: Provided is a novel compound or a salt thereof inhibiting MTHFD2 and useful for treating a disease caused by overexpression of MTHFD2, a disease involved in overexpression of MTHFD2 and/or a disease associated with overexpression of MTHFD2. Solution Provided is a sulfonamide derivative having a coumarin skeleton represented by the following formula (I) and having various substituents: wherein R1, R2, R3, R4, R5, R6 and R7 are the same as defined in the specification, and a salt thereof.
    Type: Grant
    Filed: November 22, 2017
    Date of Patent: September 15, 2020
    Assignee: Daiichi Sankyo Company, Limited
    Inventors: Masahiro Ota, Hidekazu Inoue, Junya Kawai, Hitoshi Ohki, Tadashi Toki
  • Patent number: 10774088
    Abstract: The present invention relates to an improved process for preparing [(1S,2R)-3-[[(4-aminophenyl)-sulfonyl](2-methyl-propyl)amino]-2-hydroxy-1-(phenylmethyl)-propyl]-carbamic acid (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester—which compound is also known under its INN as darunavir—by reacting carbonic acid 2,5-dioxo-1-pyrrolidinyl[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]ester with 4-amino-N-[(2R,3S)-3-amino-2-hydroxy-4-phenylbutyl]-N-(2-methylpropyl)-benzenesulfonamide in ethanol as solvent. Furthermore said process allows for darunavir to be isolated immediately in its ethanolate form, i.e. darunavir monoethanolate, which is the marketed form of darunavir under the tradename Prezista™.
    Type: Grant
    Filed: November 16, 2017
    Date of Patent: September 15, 2020
    Assignee: Janssen Sciences Ireland Unlimited Company
    Inventors: Alfred Elisabeth Stappers, Yolande Lydia Lang, Shane Barry Robinson
  • Patent number: 10774089
    Abstract: There is described a method of producing (?)-levoglucosenone, said method comprising, heating lignin to a temperature in excess of 150° C. for a time sufficient to convert a proportion of the lignin to (?)-evoglucosenone.
    Type: Grant
    Filed: April 20, 2016
    Date of Patent: September 15, 2020
    Assignee: UNIVERSITY OF YORK
    Inventors: James Hanley Clark, Mario De Bruyn, Vitaliy Lvovich Budarin
  • Patent number: 10774090
    Abstract: The present invention discloses a compound comprising the formula: wherein R is hydrogen or an alkyl group having from one to ten carbon atoms, or a compound of the formula wherein the S is replaced by CH2 or O, and optionally comprising a pharmaceutically acceptable salt or hydrate thereof. A method of treating a patient having cancer or a disease comprising administering to a patient an effective amount of the compound or pharmaceutically acceptable salt or hydrate thereof.
    Type: Grant
    Filed: January 22, 2019
    Date of Patent: September 15, 2020
    Assignee: Duquesne University of the Holy Spirit
    Inventor: Aleem Gangjee
  • Patent number: 10774091
    Abstract: The present invention generally relates to novel pharmaceutical formulations containing 2-[3,5-Bis(trifluoromethyl)phenyl]-N-{4-(4-fluoro-2-methylphenyl)-6-[(7S,9aS)-7-(hydroxymethyl)hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl]-3-pyridinyl}-N,2-dimethylpropanamide, methods of preparation thereof and their use in medical therapy.
    Type: Grant
    Filed: March 13, 2019
    Date of Patent: September 15, 2020
    Assignee: KaNDy Therapeutics Limited
    Inventors: Mike Trower, Monica Lazaro, Derek Bush, David Elder, Mary Kerr
  • Patent number: 10774092
    Abstract: In certain aspects, the invention provides a method for treating a disease or condition in a subject, the method comprising co-administering to a subject in need thereof a therapeutically effective amount of at least one ULK1-inhibiting pyrimidine, and a therapeutically effective amount of an mTOR inhibitor.
    Type: Grant
    Filed: April 19, 2019
    Date of Patent: September 15, 2020
    Assignees: SALK INSTITUTE FOR BIOLOGICAL STUDIES, SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE, YALE UNIVERSITY
    Inventors: Reuben J. Shaw, Daniel F. Egan, Nicholas Cosford, Benjamin Turk, Mitchell Vamos, Dhanya Raveendra Panickar, Matthew Chun, Douglas Sheffler
  • Patent number: 10774093
    Abstract: The invention provides synthetic intermediates and synthetic processes that are useful for preparing the antibacterial agent TXA709:
    Type: Grant
    Filed: March 30, 2018
    Date of Patent: September 15, 2020
    Assignee: Taxis Pharmaceuticals, Inc.
    Inventors: Sanjeevani Ghone, Fu-An Kang, Nareshkumar Jain, Ajit S. Parhi, Ravi Ponnaiah, Anil Kumar Soni, Siva Rami Reddy Athunuri, Thrisulapani Korrakuti, Pullarao Seelam
  • Patent number: 10774094
    Abstract: The present invention discloses crystal forms and salt forms of a 7H-pyrrolo[2,3-d]pyrimidine compounds and preparation methods thereof, and further discloses use of the crystal forms and the salt forms in the manufacture of a medicament for treating arthritis.
    Type: Grant
    Filed: November 23, 2017
    Date of Patent: September 15, 2020
    Assignee: Wuxi Fortune Pharmaceutical Co., Ltd
    Inventors: Weiwei Mao, Hao Wu, Qiang Guo, Xuejian Zheng, Yonggang Liao
  • Patent number: 10774095
    Abstract: The invention provides metal-ascorbic acid crystals and a method for synthesizing the metal-ascorbic acid crystals. The metal in the metal-ascorbic acid crystals is one of copper (Cu), gold (Au) and silver (Ag). The method for synthesizing the metal-ascorbic acid crystals includes sonicating a solution of ascorbic acid and a solvent in dark to obtain a clear solution, wherein the solvent is one of dimethylformamide (DMF) and dimethyl sulfoxide (DMSO). A metal salt is added to the clear solution, wherein the metal salt is one of copper (II) sulfate pentahydrate (CuSO4.5H2O), gold (III)-chloride (AuCl3), and silver sulfate (Ag2SO4). The clear solution is sonicated after adding the metal salt to obtain a reaction mixture. Thereafter, the reaction mixture is heated in dark. The reaction mixture is treated to facilitate solvent extraction of the metal-ascorbic acid. Finally, the metal-ascorbic acid is crystallized.
    Type: Grant
    Filed: December 9, 2015
    Date of Patent: September 15, 2020
    Assignee: THE KING ABDULAZIZ CITY FOR SCIENCE AND TECHNOLOGY
    Inventors: Nezar Hassan Khdary, Abdulaziz Almalik
  • Patent number: 10774096
    Abstract: Substituted benzoxaboroles whose structure comprises Formula (III), wherein R3 is selected from —CH3, —CH2CH3, —CH2?CH2, —CH2CH2CH3, —CH(CH3)2, —CH2CH2?CH2, and cyclopropyl, R1 and R2 are each independently selected from H, —CH3, —CH2CH3, —CH2CH2CH3, and —CH(CH3)2; compositions containing such compounds, their use in therapy, including their use as anti-mycobacterial agents, for example in the treatment of a mycobacterial infection in a mammal, and methods for the preparation of such compounds, are provided.
    Type: Grant
    Filed: February 12, 2016
    Date of Patent: September 15, 2020
    Assignees: GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED, ANACOR PHARMACEUTICALS, INC.
    Inventors: Carlos Alemparte-Gallardo, Michael Richard Kevin (Dickon) Alley, David Barros-Aguirre, Ilaria Giordano, Vincent Hernandez, Xianfeng Li, Jacob J. Plattner
  • Patent number: 10774097
    Abstract: The invention relates to chemical compound of the general structure [A-R3—X—R4] where A=[R1-R2] or [R1] R1=aryl, heteroaryl R2=alkyl, aryl, heteroaryl, carbonyl, thiocarbonyl, alkyl ester, alkyl thioester R3=O, S, NH X=closo- or nido-boron cluster R4= where Z=OH, SH, NH2 where R5 is selected from H, alkyl, aryl, heteroaryl, alkyl ether, alkyl thioether, alkylamine and R6 is selected from alkyl, aryl, heteroaryl, alkyl ether, alkyl thioether, alkylamine and where R3 and R4 are in meta or para positions to one another, to a process for preparation thereof and to the use thereof, especially in medicine, for example in the inhibition of lipoxygenase.
    Type: Grant
    Filed: October 21, 2016
    Date of Patent: September 15, 2020
    Assignee: UNIVERSITÄT LEIPZIG
    Inventors: Evamarie Hey-Hawkins, Robert Kuhnert
  • Patent number: 10774098
    Abstract: Provided is a method for separating the four optical isomers of Nahlsgen.
    Type: Grant
    Filed: September 12, 2017
    Date of Patent: September 15, 2020
    Assignees: KYOTO UNIVERSITY, NAHLS CORPORATION CO., LTD.
    Inventors: Jun Hiratake, Bunta Watanabe, Ryuzo Yoshioka, Hideaki Ishida
  • Patent number: 10774099
    Abstract: The present invention relates to a process for phospholipidation of imidazoquinolines and oxoadenines. More particularly, the present invention relates to a high-yielding and scalable procedure for the phospholipidation of imidazoquinolines and oxoadenines which obviates the need to isolate unstable phosphoramidite intermediates. This process may be used for the phospholipidation of toll-like receptor 7 (TLR7)—active and toll-like receptor (TLR8)—active imidazoquinolines and oxoadenines.
    Type: Grant
    Filed: December 12, 2016
    Date of Patent: September 15, 2020
    Assignee: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Helene G. Bazin-Lee, Laura S. Bess, David A. Johnson
  • Patent number: 10774100
    Abstract: An object t of the present invention is to proroaide crystal of a cyclic phosphonic acid sodium salt (2ccPA) with high purity and excellent storage stability and a method for producing the crystal.
    Type: Grant
    Filed: July 2, 2019
    Date of Patent: September 15, 2020
    Assignees: OTSUKA CHECMIAL CO., LTD., SANSHO CO., LTD.
    Inventors: Hiroaki Yuasa, Hiroki Okazaki
  • Patent number: 10774101
    Abstract: Optionally substituted BODIPY-Iridium complexes, such as those depicted Formula 4, may be useful in filters for display devices.
    Type: Grant
    Filed: June 5, 2018
    Date of Patent: September 15, 2020
    Assignee: NITTO DENKO CORPORATION
    Inventor: Tissa Sajoto
  • Patent number: 10774102
    Abstract: An embodiment of the present invention relates to a compound of the general formula. The compound of formula is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human. Furthermore an embodiment of the present invention concerns a method for treatment of a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human.
    Type: Grant
    Filed: January 28, 2016
    Date of Patent: September 15, 2020
    Assignee: Galecto Biotech AB
    Inventors: Thomas Brimert, Richard Johnsson, Hakon Leffler, Ulf Nilsson, Fredrik Zetterberg
  • Patent number: 10774103
    Abstract: Disclosed are steviol glycosides referred to as rebaudioside V and rebaudioside W. Also disclosed are methods for producing rebaudioside M (Reb M), rebausoside G (Reb G), rebaudioside KA (Reb KA), rebaudioside V (Reb V) and rebaudioside (Reb W).
    Type: Grant
    Filed: November 2, 2017
    Date of Patent: September 15, 2020
    Assignee: Conagen Inc.
    Inventors: Guohong Mao, Xiaodan Yu
  • Patent number: 10774104
    Abstract: Disclosed is a method for the preparation of intermediates useful in the synthesis of gemcitabine-[phenyl-benzoxy-L-alaninyl)]-phosphate. Also disclosed is a method of preparing gemcitabine-[phenyl-benzoxy-L-alaninyl)]-phosphate.
    Type: Grant
    Filed: December 9, 2016
    Date of Patent: September 15, 2020
    Assignee: Laurus Labs Private Ltd
    Inventors: Mani Bushan Kotala, Venkata Lakshmi Narasimha Rao Dammalapati
  • Patent number: 10774105
    Abstract: Phosphoramidate esters and related nucleotide analogs useful in polynucleotide sequencing techniques, and synthetic methods for preparing those compounds, are disclosed, including compounds having the following structure: wherein R1, R2, R3 and R4 are as defined herein. These compounds include nucleotide phosphoramidates analogs that are modified on the alpha-phosphate to enable attachment of a variety of application-specific substituents such as tether molecules.
    Type: Grant
    Filed: April 10, 2019
    Date of Patent: September 15, 2020
    Assignee: STRATOS GENOMICS, INC.
    Inventors: Mark Stamatios Kokoris, John Tabone, Melud Nabavi, Aaron Jacobs
  • Patent number: 10774106
    Abstract: The present invention relates to compounds of the formula I: including any possible stereoisomers thereof, wherein R9 has the meaning as defined herein, or a pharmaceutically acceptable salt or solvate thereof. The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use, alone or in combination with other HCV inhibitors, in HCV therapy.
    Type: Grant
    Filed: December 19, 2019
    Date of Patent: September 15, 2020
    Assignee: Janssen Sciences Ireland Unlimited Company
    Inventors: Ioannis Nicolaos Houpis, Tim Hugo Maria Jonckers, Pierre Jean-Marie Bernard Raboisson, Abdellah Tahri
  • Patent number: 10774107
    Abstract: Novel compositions and methods for engineering wireframe architectures and scaffolds of increasing complexity by creating gridiron-like DNA structures (FIG. 1). A series of four-arm junctions are used as vertices within a network of double-helical DNA fragments. Deliberate distortion of the junctions from their most relaxed conformations ensures that a scaffold strand can traverse through individual vertices in multiple directions. DNA gridirons, ranging from two-dimensional arrays with reconfigurability to multilayer and three-dimensional structures and curved objects, can be assembled according the methods presented herein.
    Type: Grant
    Filed: November 28, 2018
    Date of Patent: September 15, 2020
    Assignee: ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY
    Inventors: Dongran Han, Hao Yan
  • Patent number: 10774108
    Abstract: Described herein are neuroactive steroids of the Formula (II): or a pharmaceutically acceptable salt thereof; wherein A, R1, R2a, R2b, R3a, R3b, R4a, R4b, R5, R6 and are as defined herein. Such compounds are envisioned, in certain embodiments, to behave as GABA modulators. The present invention also provides pharmaceutical compositions comprising a compound of the present invention and methods of use and treatment, e.g., such for inducing sedation and/or anesthesia.
    Type: Grant
    Filed: November 27, 2015
    Date of Patent: September 15, 2020
    Assignee: Sage Therapeutics, Inc.
    Inventors: Gabriel Martinez Botella, Boyd L. Harrison, Albert Jean Robichaud, Francesco G. Salituro, Richard Thomas Beresis
  • Patent number: 10774109
    Abstract: The present invention provides a crystal of reduced glutathione having excellent powder properties and a method for producing the same. The present invention relates to a crystal of reduced glutathione, wherein the average crystal thickness is 10 ?m or more.
    Type: Grant
    Filed: March 10, 2017
    Date of Patent: September 15, 2020
    Assignee: KYOWA HAKKO BIO CO., LTD.
    Inventors: Kazunari Fukumoto, Maya Iguchi, Hiroshi Nagano
  • Patent number: 10774110
    Abstract: A compound of Formula (I), and its analogs are provided. Compositions that include Formula I can be used to inhibit human equilibrative nucleoside transporter 1, increase adenosine signaling and produce effects that include increasing antiviral activity, increasing antiparasitic activity, increasing alcohol tolerance, decreasing pain protecting from ischemia as well as many other conditions.
    Type: Grant
    Filed: February 3, 2017
    Date of Patent: September 15, 2020
    Assignee: The Johns Hopkins University
    Inventors: Jun Liu, Jingxin Wang, Zhaoli Sun, Sam Hong
  • Patent number: 10774111
    Abstract: The present invention relates to an opioid peptide represented by general formula TyrGlyGly-X1-X2-X3-X4, wherein: X1 is represented by Thr or Glu; X1 is represented by Gly or Thr or Ala; X3 is represented by Ala or Val or Gly or Glu; and X4 is represented by His or Gln or Thr or SEQ ID NO:1, or HisTyr or GlnTyr or ThrTyr. The invention also relates to pharmaceutical and food compositions comprising the peptide and to the use of the same for analgesic purposes, and/or for providing a feeling of satiety to a subject.
    Type: Grant
    Filed: August 17, 2015
    Date of Patent: September 15, 2020
    Assignees: EMBRAPA-EMPRESA BRASILEIRA DE PESQUISA AGROPECUARIA, FUNDAÇÃO UNIVERSIDADE DE BRASÍLIA—FUB—UNB
    Inventors: Carlos Bloch, Jr., Felipe Vinecky, Karla Graziella Moreira, Márcia Renata Mortari
  • Patent number: 10774112
    Abstract: Mimetic peptides having anti-angiogenic and anti-tumorigenic properties and methods of their use for treating cancer, ocular diseases, such as age-related macular degeneration, and other-angiogenesis-dependent diseases are disclosed. More particularly, an isolated peptide comprising the amino acid sequence LRRFSTAPFAFIDINDVINF, which exhibits anti-angiogenic activity in endothelial cell proliferation, migration, adhesion, and tube formation assays, anti-migratory activity in human breast cancer cells in vitro, anti-angiogenic and anti-tumorigenic activity in vivo in breast cancer xenograft models, and age-related macular degeneration models is disclosed. The isolate peptide also exhibits anti-lymphangiogenic and directly anti-tumorigenic properties.
    Type: Grant
    Filed: September 22, 2017
    Date of Patent: September 15, 2020
    Assignee: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Aleksander S. Popel, Niranjan B. Pandey, Esak Lee, Jordan J. Green, Ron B. Shmueli
  • Patent number: 10774113
    Abstract: The invention relates to novel infective agents, the use thereof for the production of a pharmaceutical composition for the treatment and prophylaxes of a disease, preferably an infectious disease, a pharmaceutical composition comprising said compound, and to methods of producing said compounds. The invention further relates to a new probiotic configured for preventing or reducing the colonization by a pathogenic microorganism of an organ of a living being.
    Type: Grant
    Filed: September 22, 2017
    Date of Patent: September 15, 2020
    Assignee: Eberhard Karls Universitaet Tuebingen
    Inventors: Bernhard Krismer, Andreas Peschel, Stephanie Grond, Alexander Zipperer, Martin Christoph Konnerth, Daniela Janek, Hubert Kalbacher, Nadine Anna Schilling
  • Patent number: 10774114
    Abstract: The invention provides polypeptides interacting with the binding of the RSV phosphoprotein P with the RSV nucleoprotein N and methods of using such polypeptides in the treatment and/or prevention of RSV infection.
    Type: Grant
    Filed: March 10, 2015
    Date of Patent: September 15, 2020
    Assignee: FONDATION THE ARK
    Inventors: Origéne Nyanguile, Jean-François Eleouet, Marie Galloux
  • Patent number: 10774115
    Abstract: A first Fab region-binding peptide includes an amino acid sequence selected from the group consisting of SEQ ID NOs: 1 to 5 with substitution of one or more amino acid residues at the 17th position and the 36th position, wherein an acid dissociation pH thereof is shifted to a neutral side. A second Fab region-binding peptide further includes deletion, substitution and/or addition of one or more amino acid residues at positions other than the 17th position and the 36th position. A third Fab region-binding peptide includes an amino acid sequence with a sequence identity of 80% or more to the amino acid sequence of the first Fab region-binding peptide.
    Type: Grant
    Filed: August 25, 2017
    Date of Patent: September 15, 2020
    Assignee: KANEKA CORPORATION
    Inventor: Shinichi Yoshida
  • Patent number: 10774116
    Abstract: The present invention provides a recombinant protein capable of binding to complement factor H (CFH), and thereby inducing increased binding of C3d and C3b by bound CFH compared to unbound CFH. Methods and medical devices for using utilising the same are also described.
    Type: Grant
    Filed: July 6, 2018
    Date of Patent: September 15, 2020
    Assignee: The University Court of the University of Edinburgh
    Inventors: Paul Barlow, Andrew Herbert, Elisavet Makou
  • Patent number: 10774117
    Abstract: In one aspect, the invention relates to an immunogenic composition that includes a mutant Clostridium difficile toxin A and/or a mutant Clostridium difficile toxin B. Each mutant toxin includes a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-type C. difficile toxin. The mutant toxins may further include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to antibodies or binding fragments thereof that binds to said immunogenic compositions. In further aspects, the invention relates to isolated nucleotide sequences that encode any of the foregoing, and methods of use of any of the foregoing compositions.
    Type: Grant
    Filed: July 12, 2017
    Date of Patent: September 15, 2020
    Assignee: Wyeth LLC
    Inventors: Kathrin Ute Jansen, Annaliesa Sybil Anderson, Robert G. K. Donald, Maninder K. Sidhu, Narender K. Kalyan, Justin Keith Moran, Mark E. Ruppen, Michael James Flint
  • Patent number: 10774118
    Abstract: The present invention provides a family of non-naturally occurring polypeptides having cholesterol efflux activity that parallels that of full-length apolipoproteins (e.g., Apo AI and Apo E), and having high selectivity for ABCA1 that parallels that of full-length apolipoproteins. Further, the peptides of the invention have little or no toxicity when administered at therapeutic and higher doses. The invention also provides compositions comprising such polypeptides, methods of identifying, screening and synthesizing such polypeptides, and methods of treating, preventing or diagnosing diseases and disorders associated with dyslipidemia, hypercholesterolemia, or inflammation; or diseases involving abnormal glucose metabolism, e.g., diabetes, metabolic syndrome; or Alzheimer's Disease or frontotemporal dementia.
    Type: Grant
    Filed: June 27, 2018
    Date of Patent: September 15, 2020
    Assignee: The Regents of the University of California
    Inventors: John K. Bielicki, Jan Johansson, Waleed Danho
  • Patent number: 10774119
    Abstract: The present invention relates to novel, specific-binding therapeutic and/or diagnostic polypeptides directed against the target of Swiss Prot Q16552 and novel, specific-binding therapeutic and/or diagnostic polypeptides directed against the target of Swiss Prot Q9NPF7. In addition, the present invention relates to novel, specific-binding therapeutic and/or diagnostic polypeptides directed against one or both of Swiss Prot Q16552 and Swiss Prot Q9NPF7. The invention also relates to nucleic acid molecules encoding such polypeptides and to methods for generation of such polypeptides and nucleic acid molecules. In addition, the invention is directed to compositions comprising the polypeptides, and therapeutic and/or diagnostic uses of these polypeptides.
    Type: Grant
    Filed: May 20, 2015
    Date of Patent: September 15, 2020
    Assignee: Pieris Pharmaceuticals GmbH
    Inventors: Marlon Hinner, Alexander Wiedenmann, Andrea Allersdorfer
  • Patent number: 10774120
    Abstract: The disclosure pertains to conformational epitopes in A-beta, antibodies thereto and methods of making and using immunogens and antibodies specific thereto.
    Type: Grant
    Filed: November 9, 2016
    Date of Patent: September 15, 2020
    Assignee: The University of British Columbia
    Inventors: Neil R. Cashman, Steven S. Plotkin
  • Patent number: 10774121
    Abstract: The disclosure relates generally to neurodegenerative disorders and more specifically to a group of presenilin/G-protein/c-src binding polypeptides and methods of use for modulating signaling and progression of Alzheimer's disease.
    Type: Grant
    Filed: February 21, 2019
    Date of Patent: September 15, 2020
    Assignee: The Regents of the University of California
    Inventors: Nazneen Dewji, S. Jonathan Singer
  • Patent number: 10774122
    Abstract: The present disclosure relates to compositions and methods for cancer therapy, including but not limited to, targeted inhibition of cancer markers. In particular, the present disclosure relates to recurrent gene fusions as clinical targets for cancer.
    Type: Grant
    Filed: March 19, 2018
    Date of Patent: September 15, 2020
    Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Arul Chinnaiyan, Xiaoju Wang